Rosen Law Firm

Rosen Law Firm Probes Gildan Activewear Over Short-Seller Fallout

NEW YORK – September 12, 2026 -- Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Gildan Activewear Inc. (NYSE: GIL) following allegations that the apparel maker issued materially misleading information to investors.

Short seller report triggers 18.7% share drop on June 16, 2026

The inquiry centers on a June 16, 2026 Investing.com article reporting that Gildan Activewear shares fell after Jehoshaphat Research released a short report disclosing a short position in the Canadian manufacturer. The research firm alleged that Gildan's organic growth has been negative for years despite reported revenue growth, claiming the underlying decline was obscured through financial engineering. On that news, Gildan Activewear's NYSE-listed shares dropped 18.7% in a single session.

Rosen Law Firm Probes Putnam Investments Over Misleading Disclosures

New York – September 12, 2026 -- Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC on behalf of investors in the firm's stock-based mutual funds, citing allegations that Putnam may have issued materially misleading business information to the investing public.

Rosen Law Firm targets investors who purchased Putnam mutual funds

The firm is preparing a prospective class action seeking recovery of investor losses tied to the alleged misstatements. Investors who purchased Putnam mutual funds may pursue compensation through a contingency fee arrangement, meaning no upfront out-of-pocket costs.

Rosen Law Files Class Action Against Unicycive Over FDA Disclosure Lapses

New York – September 12, 2026 -- Rosen Law Firm has filed a securities class action against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) covering purchasers of the company's securities between December 29, 2025 and June 29, 2026.

Lawsuit alleges Unicycive never audited its manufacturing vendor's facility

The complaint claims Unicycive had not inspected its third-party manufacturing vendor's plant or verified compliance with current good manufacturing practices, leaving the company without a reasonable basis to assert the vendor had fixed deficiencies previously cited by the U.S. Food and Drug Administration.